Savvy developers are realizing the advantages of writing explicit, consistent, well-documented code that agents easily understand. Boring makes agents more reliable.
SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...
Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...
IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...
Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: Australia and INDIANAPOLIS, March 10, ...
In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows.CARMEL, Ind., March 09, 2026 (GLOBE ...
A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.
Stop falling for misleading headlines. Understand the difference between correlation and causation, and learn how researchers prove real scientific facts.
In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...
Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.
In veterans with type 2 diabetes, treatment with GLP-1 receptor agonists was associated with a reduced risk for various substance use disorders compared with sodium-glucose cotransporter-2, or SGLT-2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results